About FPR – Who we are and What we do
Forerunner Pharma Research Co., Ltd. (FPR) was founded as a joint venture by Chugai Pharmaceutical Co., Ltd., Mitsui & Co., Ltd., and Central Institute for Experimental Animals in April 2005. FPR made a new start as a wholly owned subsidiary of Chugai Pharmaceutical Co., Ltd. (Chugai) in September 2011, and has been pursuing research to effectively produce antibody drug candidates utilizing pathological and genome information. innovative genomic drug discovery.
Currently FPR is active at 3 research laboratories, Komaba Open Laboratory of Tokyo University, National Cancer Center (NCC) and Molecular & Life Innovation of Tokyo University (MLI). Along with advanced technology and information held by academic and external research institutes, FPR combines Chugai’s proprietary drug development expertise to explore innovative drug discovery seeds through identifying and assaying molecular targets.
About Chugai Pharmaceutical Co., Ltd. (Chugai)
Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. Chugai, based in Tokyo, specializes in prescription pharmaceuticals and is listed on the 1st section of the Tokyo Stock Exchange. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy unmet medical needs, mainly focusing on the oncology area.